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i.org/1extent to which CKD increases the risk of thromboembolism in patients with nonvalvular
AF and the beneﬁts of anticoagulation in this group remain unclear. We addressed the role
of CKD in the prediction of thromboembolic events and the impact of anticoagulation using
a meta-analysis method. Data sources included MEDLINE, EMBASE, and Cochrane (from
inception to January 2014). Three independent reviewers selected studies. Descriptive and
quantitative information was extracted from each selected study and a random-effects
meta-analysis was performed. After screening 962 search results, 19 studies were consid-
ered eligible. Among patients with AF, the presence of CKD resulted in an increased risk
of thromboembolism (hazard ratio [HR] 1.46, 95% conﬁdence interval [CI] 1.20 to 1.76,
p [ 0.0001), particularly in case of end-stage CKD (HR 1.83, 95% CI 1.56 to 2.14,
p <0.00001). Warfarin decreased the incidence of thromboembolic events in patients with
noneend-stage CKD (HR 0.39, 95% CI 0.18 to 0.86, p <0.00001). Recent data on novel oral
anticoagulants suggested a higher efﬁcacy of these agents compared with warfarin (HR
0.80, 95% CI 0.66 to 0.96, p[ 0.02) and aspirin (HR 0.32, 95% CI 0.19 to 0.55, p <0.0001)
in treating noneend-stage CKD. In conclusion, the presence of CKD in patients with AF is
associated with an almost 50% increased thromboembolic risk, which can be effectively
decreased with appropriate antithrombotic therapy. Further prospective studies are needed
to better evaluate the interest of anticoagulation in patients with severe CKD.  2014
Elsevier Inc. All rights reserved. (Am J Cardiol 2014;114:646e653)Thromboembolic events are one of the most feared
complications of atrial ﬁbrillation (AF).1 Chronic kidney
disease (CKD) is relatively prevalent in patients with AF.2
The extent to which the presence of CKD may increase
the risk of thromboembolism in patients with AF has not yet
been fully elucidated. Oral anticoagulation is the mainstay
of thromboembolic prevention in patients with AF,3 but data
on efﬁcacy and safety in the CKD and dialysis population
have been scarce and contradictory.4,5 Our aim was to
systematically evaluate, through a meta-analysis method,
the impact of the presence of CKD in patients with AF as
regards risk of thromboembolism and the potential beneﬁt of
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We performed a search in MEDLINE (by way of Ovid
and PubMed), EMBASE, and Cochrane (from inception to
January 3, 2014) databases using the following search
string: “atrial ﬁbrillation” AND (“renal failure” OR “chronic
renal disease” OR “dialysis”) AND (“stroke” OR “throm-
boembolism”). The reference lists of the accessed full-text
reports were further researched for sources of potential in-
formation relevant to this analysis. The authors of full-text
reports and abstracts were contacted by e-mail to retrieve
additional information.
Only longitudinal studies assessing the occurrence of a
composite end point of stroke or systemic embolism (and
including transient ischemic attack) during follow-up in pa-
tients with AF were considered for inclusion. Both registries
and randomized trials were considered eligible for analysis.
The methods sections of evaluated studies were reviewed to
conﬁrm the suitability and composition of the reported end
point. Studies assessing only stroke (either ischemic, hem-
orrhagic, or a composite of both) and providing no data on
systemic embolism were not considered representative of the
full spectrum of thromboembolism in AF and were excluded
from analysis. Similarly, studies only reporting stroke or
systemic embolism in association with myocardial infarction,
hospitalization, or death not due to stroke or systemic
embolism were not included.www.ajconline.org
Figure 1. Flowchart diagram illustrating study selection.
Review/CKD and Thromboembolism in AF 647To be included in the systematic review, the studies
needed to have a design allowing extraction of information
concerning at least 1 of the 2 main aims of this study: (1)
assessment of the incidence of stroke and systemic embo-
lism in patients with AF according to the presence of CKD
(including dialysis treatment) and (2) estimating the impact
of anticoagulation in patients with CKD and AF. The pop-
ulation, intervention, comparison, and outcome approach
was used for this aim.6 The population of interest included
patients with nonvalvular AF with CKD or treated with
dialysis. The term end-stage CKD was used for patients with
disease requiring renal replacement therapy, either dialysis
or transplantation. Noneend-stage CKD was used for the
remaining patients with renal disease. The intervention was
anticoagulation. Comparisons were performed among thefollowing groups: adjusted-dose warfarin (target interna-
tional normalized ratio of 2 to 3) versus no treatment, aspirin
or low dosage noneadjusted-dose warfarin (target interna-
tional normalized ratio <1.5); warfarin versus novel oral
anticoagulants; and novel oral anticoagulants versus aspirin.
The outcome has been deﬁned previously.
Two independent reviewers (RP and SCB) screened all
abstracts and titles to identify potentially eligible studies.
The full text of these potentially eligible studies was then
evaluated to determine the eligibility of the study for the
review and meta-analysis. Disagreements regarding eligi-
bility were resolved by consensus with the help of a third
reviewer (SB).
Data extraction and presentation for the preparation of
this report followed the recommendations of the Preferred
Table 1
Selected studies for the systematic review: baseline information and main ﬁndings
Author, Ref Study Design,
Acronym
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Review/CKD and Thromboembolism in AF 649Reporting Items for Systematic Reviews and Meta-Analyses
group.7 The following data were extracted for characterizing
each patient sample in the selected studies, whenever avail-
able: criteria for deﬁningCKD, number of patients with CKD
(and when available, number in each estimated glomerular
ﬁltration rate [eGFR] category of the National Kidney
FoundationeKidney Disease Outcomes Quality Initiative
classiﬁcation8) or on dialysis in each study, and type and
frequency of antithrombotic treatment (warfarin or other
vitamin K antagonists, novel oral anticoagulants, aspirin, or
other antiplatelet agents).
Data were pooled using random effects, according to the
Mantel-Haenszel model, through Review Manager (Rev-
Man), version 5.1 (The Nordic Cochrane Center, The
Cochrane Collaboration, 2011, Copenhagen, Denmark). The
measurement of treatment effect and AF, CKD, or dialysis
exposure was performed using dichotomous adjusted hazard
ratios (HR) and 95% conﬁdence intervals (CI). Pairwise
comparisons were performed for the primary end point in the
settings deﬁned in the third paragraph of the Methods section.
Comparison of the treatment effect of adjusted-dose warfarin
versus the novel oral anticoagulants was performed through
the use of risk ratios (number of events or the incidence in each
treatment group) from randomized controlled trials. Addi-
tional sensitivity analyses were performed, whenever data
were available, regarding end-stage CKD on dialysis treat-
ment. Statistical heterogeneity on eachoutcomeof interestwas
assessed and quantiﬁed using the Cochran Q test and the I2
statistic, respectively. The I2 statistic describes the percentage
of total variation across studies due toheterogeneity rather than
chance. Values of <25%, 25% to 50%, and >50% are by
convention classiﬁed low, moderate, and high degrees of
heterogeneity, respectively. The presence of publication bias
was evaluated through the use of funnel plots if the appropriate
requisites concerning the minimum number of included
studies in a forest plot were met (at least 10 studies).9
Results
Overall, 962 entries were retrieved for title and abstract
analysis. Of these, 783 were excluded as they did not meet
inclusion criteria for the meta-analysis and 106 were dupli-
cate entries. The remaining 73 studies were carefully evalu-
ated, and after full-text review, only 19 studies (all full-text
reports) were ﬁnally considered eligible.2,5,10e26 The step-
wise selection process is illustrated in Figure 1. There was
complete agreement between investigators on the inclusion
of all the selected trials. Information on risk stratiﬁcation,
study design, number of participants, and themainﬁndings in
each study are provided in Table 1. Following the predeﬁned
inclusion and exclusion criteria,5 studies were included in
each of the traced forest plots. Accordingly, no funnel plots
were drawn.
Of the selected studies, 10 provided information con-
cerning the impact of CKD on the incidence of stroke or
systemic embolism in patientswithAF.2,5,10,12,13,15,17,18,20,21
Different equations were used for estimating the eGFR and
classifying patients as having CKD: Cockcroft-Gault for-
mula was used in 5 studies15,18,20,21,25 and the Modiﬁcation
of Diet in Renal Disease was used in 5.2,10,12,23,25 Also, in 2
investigations21,25 the chronic kidney disease epidemiology
Figure 2. Forest plots illustrating the association of stroke or systemic embolism with the presence of kidney disease in patients with AF. IV ¼ inverse variance;
IS ¼ ischemic stroke; SE ¼ systemic embolism; TIA ¼ transient ischemic attack; US ¼ stroke of uncertain origin.
Figure 3. Forest plot illustrating the effect of anticoagulation on the incidence of stroke or systemic embolism in patients with AF and CKD. IV ¼ inverse
variance; IS ¼ ischemic stroke; SE ¼ systemic embolism; TIA ¼ transient ischemic attack.
Figure 4. Forest plot illustrating the comparison of warfarin versus the novel oral anticoagulants in the prevention of stroke or systemic embolism in patients
with CKD. HS ¼ hemorrhagic stroke; IS ¼ ischemic stroke; M-H ¼ Mantel-Haenszel; NOA ¼ novel oral anticoagulants; SE ¼ systemic embolism; US ¼
stroke of uncertain origin.
650 The American Journal of Cardiology (www.ajconline.org)collaboration and cystatin C clearance were also used for
assessing the safety and efﬁcacy of apixaban and dabigatran at
different levels of eGFR. The remaining selected studies for
the systematic review did not use any of these, because the
diagnosis of CKD was retrieved from codiﬁcation.5,13,14 A
cutoff of 50 to 60ml/minwas used inmost studies for deﬁning
the presence of CKD.
According to data on Figure 2, in patients with AF the
presence of CKD was associated with a higher rate of
thromboembolic events (HR 1.46, 95% CI 1.20 to 1.76, p ¼
0.0001). All included studies were in favor of the associa-
tion of CKD with an increase in thromboembolism inpatients with AF. However, their high heterogeneity is
shown by the I2 statistic of 80%. Information concerning
the risk of stroke or systemic embolism in patients with AF
who were also on dialysis was provided by only 1 study: in
the national Danish registry thromboembolism was found to
be increased in this speciﬁc population (HR 1.83, 95% CI
1.56 to 2.14, p <0.00001).5
Baseline data, design, and the main ﬁndings of
trials providing information regarding warfarin in this
setting5,15,17,18,20,21,23,25 are listed in Table 1. Information
concerning time in therapeutic range is only known for the 3
included randomized controlled trials of the novel oral
Review/CKD and Thromboembolism in AF 651anticoagulants controlled with warfarin (64% in Randomized
Evaluation of Long-Term Anticoagulation Therapy
[RE-LY],25 55% in Rivaroxaban Once-Daily, Oral, Direct
Factor Xa Inhibition Compared With Vitamin K Antagonism
for Prevention of Stroke and Embolism Trial in Atrial Fibril-
lation [ROCKET-AF],18 and 62% in Apixaban for Reduction
In STroke and Other ThromboemboLic Events in atrial ﬁbril-
lation [ARISTOTLE]21 trials). As regards the presence of
heparin treatment in patients on dialysis, this information was
absent or lacked details concerning the protocol used in the
included studies.
The use of warfarin was associated with a major decrease
in thromboembolic events (HR 0.39, 95% CI 0.18 to 0.86,
p <0.00001) in patients with CKD. The effect was present
in all studies but one (which revealed a strong trend for
beneﬁt of warfarin; Figure 3). Despite the overall favorable
trend, a high heterogeneity, I2 statistic of 91%, was observed
driven by the differences in treatment effect. Only 1 study
assessing the role of warfarin in the prevention of throm-
boembolism in patients on dialysis met the inclusion criteria
for this meta-analysis. There, warfarin displayed a protective
effect (HR 0.44, 95% CI 0.26 to 0.74, p ¼ 0.002). Also, the
use of warfarin did not lead to an increased risk of bleeding
(HR 1.27, 95% CI 0.91 to 1.77, p ¼ 0.15).5
In Table 1, data concerning renal function subanalysis of
4 randomized controlled trials involving the use of the novel
oral anticoagulants in patients with AF are listed. In the
Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent
Stroke in Atrial Fibrillation Patients Who Have Failed or
Are Unsuitable for Vitamin K Antagonist Treatment
(AVERROES) trial, aspirin was the treatment of the control
arm, and in the others, the RE-LY, ROCKET-AF, and
ARISTOTLE trials, warfarin was used. Data concerning the
effectiveness of the novel oral anticoagulants versus
warfarin and also versus aspirin in patients with CKD
(moderate or preterminal CKD) and AF are shown in
Figure 4. A very low level of heterogeneity was found
among the 3 selected trials (I2 ¼ 0%) showing an overall
beneﬁt of the novel oral anticoagulants compared with
warfarin (HR 0.80, 95% CI 0.66 to 0.96, p ¼ 0.02).
Apixaban was more effective than aspirin in preventing
stroke or systemic embolism in the noneend-stage CKD
population (HR 0.32, 95% CI 0.19 to 0.55, p <0.0001). In
these novel oral anticoagulants trials, only a small minority
of patients had eGFR <30 ml/min15,21 and no patients on
dialysis were included.
Discussion
The observed ﬁndings in this meta-analysis suggest an
increased risk of thromboembolism when CKD is present in
patients with AF, with an incremental relation between the
severity of renal dysfunction and the risk of thromboembolism.
Anticoagulation seems to be effective in decreasing thrombo-
embolic events in noneend-stage CKD, with a particular
beneﬁt of novel oral anticoagulants in the moderate CKD
population (eGFR 30 to 60 ml/min) with AF. Regarding end-
stage CKD, data result from a single large national registry
and seem in favor of beneﬁt from warfarin. However, data on
the novel oral anticoagulants in patients with end-stage or se-
vere CKD with eGFR<25 to 30 ml/min are currently lacking.Preliminary evidence has suggested that adding CKD
to the currently available risk stratiﬁcation schemes for
thromboembolism in patients with AF may be worth further
evaluation. In a subanalysis of the AVERROES trial, when
adjusting for the CHADS2 score in multivariate analysis, stage
III CKD remained an independent predictor of stroke or sys-
temic embolism (HR 1.6, p <0.01).15
Piccini et al have tested the impact of adding CKD to the
CHADS2 score and developed the R2CHADS2 score
(CHADS2 plus 2 points if creatinine clearance <60 ml/min).
This was derived from the ROCKET-AF cohort and vali-
dated in the Anticoagulation and Risk Factors in Atrial
Fibrillation (ATRIA) study population. They found that,
when using the R2CHADS2 score, almost 20% of patients
were successfully reclassiﬁed into a more appropriate risk
category (i.e., it improved the net reclassiﬁcation index by
17.4% relative to CHADS2; 95% CI 12.1% to 22.5%), even
if C statistics displayed similar values (CHADS2 ¼ 0.673 vs
R2CHADS2 ¼ 0.672).19
A score comprising8 variables (age, previous stroke, female
gender, diabetes mellitus, heart failure, hypertension, protein-
uria, and eGFR <45 ml/min or end-stage renal disease) has
been recently derived using data from the ATRIA cohort. Its
external validation has shown promising results with higher C
statistics (0.70; 95% CI 0.67 to 0.72) than the CHADS2 (0.66;
95% CI 0.64 to 0.69) or CHA2DS2-VASc (0.68; 95% CI 0.66
to 0.70) score for the discrimination of all thromboembolic
events.24 The discriminative performance of this score was
even better if only severe thromboembolic events were
considered (C statistic¼ 0.75; 95%CI 0.73 to 0.78), remaining
better than CHADS2 (C statistic¼ 0.71; 95% CI 0.68 to 0.73)
and CHA2DS2-VASc (C statistic¼ 0.72; 95%CI 0.69 to 0.74)
scores. When assessing the net reclassiﬁcation improvement
obtained by the use of the new score, it was veriﬁed that 24% to
25%ofpatientswere correctly reclassiﬁed into an adequate risk
category, compared with CHADS2 and CHA2DS2-VASc
scores, respectively (the percentage increased to 33% if only
severe events were measured).
In contrast, different ﬁndings were observed by Roldan
et al in a smaller population of patients with nonvalvular AF
stable on oral anticoagulation for >6 months, where adding
eGFR (1 point to eGFR 30 to 59 ml/min and 2 points to
<30 ml/min) to the CHADS2 and CHA2DS2-VASc scores
resulted in no signiﬁcant improvement in C statistics or in-
tegrated discrimination improvement.10 In addition, Banerjee
et al found that renal impairment and/or eGFR (codiﬁed as 3
different categories: <30, 30 to 59, and 60 ml/min) did not
increase the risk of ischemic stroke or systemic thromboem-
bolism after adjustment for the CHADS2 risk factors. Thus, if
added to CHADS2 or CHA2DS2-VASc risk scores, eGFR did
not independently add to the predictive value of any of
these.12
The increased risk of thromboembolism when CKD is
present may be explained by the coexistent platelet dysfunc-
tion, a prothrombotic and inﬂammatory state, andmore severe
vascular disease, frequently found in these patients.2 It has
also been proposed that the presence of CKDmay be amarker
of target organ lesion.27 Furthermore, an association of low
eGFR with an increased prevalence of markers of left atrial
stasis (dense spontaneous echocardiographic contrast and low
ﬂow velocities in the left atrial appendage) in patients withAF
652 The American Journal of Cardiology (www.ajconline.org)on transesophageal echocardiogrammay also account for this
thromboembolic trend.28
Oral anticoagulants were advantageous in the prevention of
stroke or systemic embolism in patients with noneend-stage
CKD. Among patients on dialysis, the only study assessing the
efﬁcacy of warfarin in the prevention of thromboembolism
demonstrated a beneﬁt of this drug.5 Besides scarcity of data,
the increased risk of hemorrhagic stroke in this population
when treated with warfarin29 may deter the practicing physi-
cian from starting anticoagulation.
The observed advantage of the novel oral anticoagulants in
the eGFR 30 to 60 ml/min strata mimics the results observed
in meta-analysis of the recent trials involving these agents,30
suggesting that their advantage concerning efﬁcacy is main-
tained despite the presence of moderate CKD. Also, accord-
ing to data from the subanalysis of theAVERROES trial in the
stage III CKD population, apixaban displays a higher efﬁcacy
compared with aspirin, with a similar bleeding risk.15 How-
ever, only a minority of patients with eGFR 25 to 30 ml/min
and nonewith lower eGFR values have been included in these
trials, which does not allow any ﬁrm conclusions concerning
the use of these agents in those speciﬁc types of patients.
There are several limitations to this investigation, which
are in part inherent to the meta-analysis method: some of the
selected studies were small and the majority was retrospec-
tive. Different methods for stroke deﬁnition have been used
(e.g., with variable usage of imaging), and some uncertainties
also remain concerning the chosen AF classiﬁcation in some
studies or even the reliability of its identiﬁcation. Further-
more, a high heterogeneity of the assessed populations was
illustrated by the relatively elevated I2 score in most forest
plots.
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